Whoever takes the order is rarely whoever fills the vial. A telehealth brand runs the intake, the prescribing and the billing; a pharmacy somewhere else does the chemistry. Which pharmacy that is decides the things a buyer will never be able to inspect, and it is a separate question from what ends up in the container. Federal law sorts those pharmacies into two categories with markedly different oversight, and knowing which one you are buying from is the piece of homework worth doing first.
Federal law recognizes two kinds of compounder
The split dates from a disaster. Contaminated drugs prepared by a Massachusetts pharmacy in 2012 caused more than 750 infections and more than 60 deaths across 20 states, and Congress responded with the Drug Quality and Security Act, enacted on November 27, 2013.[1]That statute is why the category question exists at all.
Section 503A of the Federal Food, Drug, and Cosmetic Act sets out the conditions under which a compounded preparation is exempt from three things at once: premarket approval, current good manufacturing practice requirements, and labeling with adequate directions for use. One of those conditions is that the drug be compounded against a valid patient-specific prescription.[1]
The same act created section 503B, a voluntary category known as outsourcing facilities. Unlike compounders operating under 503A, they are subject to those manufacturing requirements, and they may ship either against a patient-specific prescription or against an order that names no individual patient at all, such as hospital office stock.[1]Both routes are lawful. They are simply not the same undertaking.
What inspected means on each side
Day-to-day oversight of a state-licensed pharmacy that has not registered as an outsourcing facility sits mainly with its state board of pharmacy, with the FDA conducting surveillance and for-cause visits.[2]A registered outsourcing facility is overseen primarily by the FDA and inspected on a risk-based schedule, and it also has to report adverse events and tell the agency what it compounds.[1]
The agency puts the standards question plainly: quality standards differ depending on where compounding occurs, and drugs compounded in outsourcing facilities are subject to manufacturing requirements that drugs compounded under 503A conditions are not.[2] None of that establishes that one category produces a better vial than the other on any given day. It establishes who turns up, how often, and against which rulebook.
Registration is not approval
The FDA publishes a weekly table of facilities that have registered under 503B, and the columns are the useful part. Each row shows the date of the last inspection, whether a Form 483 was issued, whether a recall was conducted, and what action followed. Some rows say nothing has happened yet: at the update published on September 8, 2026, the table listed 95 facilities, and 40 of those carried the entry “Not yet inspected.”[3]
Appearing on that list means a facility filed complete registration information, which is a fact about paperwork rather than a judgment about product. And it changes nothing about the underlying status described in the article on approval: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed.[2] A seller citing a 503B relationship has told you something real and something narrow.
What a certification seal actually certifies
Many sites in this category display a LegitScript badge. That program asks whether a merchant is adequately licensed for the services it offers in the jurisdictions it serves, and whether it has disclosed prior criminal, regulatory or civil violations. It also covers whether affiliates and partner pharmacies operate legally, whether prescriptions are valid, and whether marketing claims are accurate rather than misleading.[4] That is a serious list.
Two limits are worth holding onto. A badge on a page is an image file, and an image proves only that somebody pasted it; the certifier runs a public status lookup, and a name either appears there or it does not. Second, certifying the merchant is a different act from certifying the pharmacy behind it, so a certified storefront still leaves the supplier question open.
Most sellers never name the pharmacy
This is the disclosure gap that matters, and the agency has named it directly. Consumers buying compounded drugs through online pharmacies and telehealth platforms may not know the identity of the compounder that produced the drug. That includes whether the compounder meets appropriate quality standards, and whether it is appropriately licensed and regulated.[2]
That description fits this market closely. Of the sellers whose published pricing sits behind the semaglutide board and the tirzepatide board, a small minority say anything about who prepares the medication on the pages where they publish a price. A few name a specific pharmacy. A few more state a category, 503A or 503B, without a name attached. The rest say nothing at all, which is not evidence of a poor pharmacy — it is the absence of the one fact that would let anyone check. What each company does publish is recorded in the individual seller write-ups.
Why the missing name travels further than you think
A study of a nationwide primary-care records database looked at 153,044 patients with documented semaglutide or tirzepatide use between 2021 and 2024. Compounded formulations appeared in the notes for 8.2% of them, against survey estimates that roughly 23% of people taking these drugs obtained them from compounders.[5] The authors read the gap as a sign that many patients are getting these medications outside coordinated care.
A prescriber reviewing a chart cannot weigh a product that is not in it, and cannot look up a pharmacy that has no name. Getting the supplier in writing is not only consumer diligence; it is the thing that makes the purchase legible to everyone else involved in the care.
Six questions, and what a non-answer means
Which pharmacy prepares the medication, by name? Is it a state-licensed pharmacy operating under 503A, or a facility registered with the FDA under 503B? If it is registered, what does its row in the federal table show for its last inspection? If it is state-licensed, which board issues the license, and is that license current and unrestricted?
Two more finish the set. Does the seller’s own certification appear in the certifier’s public lookup rather than only as a badge on the checkout page? And will support put the answers in writing before the first charge, in a chat transcript or an email, rather than describing them over the phone?
A company that answers all six has handed over material that can be verified against public records without taking anything on trust. A company that declines has not proven anything against itself, and it has also not given you a single thing to check. How that difference is weighed on this site, and what it can and cannot support, is set out in the methodology.